Novel variants in established epilepsy genes in focal epilepsy.


Journal

Seizure
ISSN: 1532-2688
Titre abrégé: Seizure
Pays: England
ID NLM: 9306979

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 28 03 2023
revised: 30 05 2023
accepted: 06 06 2023
medline: 4 8 2023
pubmed: 1 7 2023
entrez: 30 6 2023
Statut: ppublish

Résumé

Next generation sequencing (NGS) has greatly expanded our understanding of genetic contributors in multiple epilepsy syndromes, including focal epilepsy. Describing the genetic architecture of common syndromes promises to facilitate the diagnostic process as well as aid in the identification of patients who stand to benefit from genetic testing, but most studies to date have been limited to examining children or adults with intellectual disability. Our aim was to determine the yield of targeted sequencing of 5 established epilepsy genes (DEPDC5, LGI1, SCN1A, GRIN2A, and PCHD19) in an extensively phenotyped cohort of focal epilepsy patients with normal intellectual function or mild intellectual disability, as well as describe novel variants and determine the characteristics of variant carriers. Targeted panel sequencing was performed on 96 patients with a strong clinical suspicion of genetic focal epilepsy. Patients had previously gone through a comprehensive diagnostic epilepsy evaluation in The Neurology Clinic, University Clinical Center of Serbia. Variants of interest (VOI) were classified using the American College of Medical Genetics and the Association for Molecular Pathology criteria. Six VOI in eight (8/96, 8.3%) patients were found in our cohort. Four likely pathogenic VOI were determined in six (6/96, 6.2%) patients, two DEPDC5 variants in two patients, one SCN1A variant in two patients and one PCDH19 variant in two patients. One variant of unknown significance (VUS) was found in GRIN2A in one (1/96, 1.0%) patient. Only one VOI in GRIN2A was classified as likely benign. No VOI were detected in LGI1. Sequencing of only five known epilepsy genes yielded a diagnostic result in 6.2% of our cohort and revealed multiple novel variants. Further research is necessary for a better understanding of the genetic basis in common epilepsy syndromes in patients with normal intellectual function or mild intellectual disability.

Identifiants

pubmed: 37390664
pii: S1059-1311(23)00158-9
doi: 10.1016/j.seizure.2023.06.005
pii:
doi:

Substances chimiques

PCDH19 protein, human 0
Protocadherins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

146-152

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Authors declare that they have no known financial interests, affiliations, or personal interests or beliefs, that could be perceived to affect the objectivity or neutrality of the manuscript.

Auteurs

Maša Kovačević (M)

Neurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia. Electronic address: massa.kovacevic@gmail.com.

Ognjen Milićević (O)

Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Marija Branković (M)

Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Milena Janković (M)

Neurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia.

Ivana Novaković (I)

Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Dragoslav Sokić (D)

Neurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Aleksandar Ristić (A)

Neurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Jannah Shamsani (J)

GenieUs Genomics, Darlinghurst, Australia.

Nikola Vojvodić (N)

Neurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH